Landis John B. 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Mar 2, 2021
Insider Transaction Report
Form 4
Landis John B.
Director
Transactions
- Exercise/Conversion
Common Stock
2021-02-28+1,900→ 5,900 total - Exercise/Conversion
Restricted Stock Units
2021-02-28−1,900→ 0 totalExercise: $0.00From: 2021-02-28→ Common Stock (1,900 underlying)
Footnotes (1)
- [F1]Fully vested on the one-year anniversary of the grant date.